ClinicalTrials.gg
RecruitingNCT05939934ORTAPUpdated Apr 6, 2026

Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal

An interventional study of Mandibular advancement device treatment in Sleep Apnea, Obstructive and Endothelial Dysfunction, sponsored by University Hospital, Angers. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.

Planned enrollment
77th of 133
40 · median 52
Started
2024
with 8 others
No phase
105 of 201
18 open now
Primary completion
2026-11
later than 19 of 47 live
Registered
166th of 201
by date
Lead sponsor
5 of 201
University Hospital, Angers

Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 77th largest by planned enrollment of the 133 interventional ones that give a count, is one of 9 that started in 2024, is one of 105 with no phase, reaches primary completion later than 19 of the 47 other live ones, and was the 166th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Sleep Apnea, Obstructive with a site in France, or all of them as a file.
02

Study summary

Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences. Continuous positive pressure (CPAP), the main treatment for OSAHS, is effective on the majority of symptoms but restrictive, which can promote non-compliance. Treatment interruptions are often observed in connection with intercurrent events such as nasal obstructions or even when patients are on the move. However, randomized trials have shown that stopping treatment, even for a short time, leads to a recurrence of symptoms and significant CV disturbances (increase in blood pressure, endothelial dysfunction, cardiac repolarization disorders). It seems important to consider strategies that promote therapeutic continuity. The mandibular advancement device (MAD) is an interesting tool in this regard. MAD is as effective as CPAP on symptoms and CV data. The investigators want to assess its effectiveness as a complementary treatment during treatment discontinuation on the main consequences of OSAHS.

Read the detailed description

Patients are recruited during sleep consultations in the Angers University Hospital pneumology department among patients followed for severe OSAHS and treated with CPAP. All of the scheduled examinations are carried out in the sleep laboratory of the CHU d'Angers.

Patients meeting the inclusion criteria and not having any non-inclusion criteria are randomized to the "MAD" group or to the "control" group. For patients in the "MAD" group, an appointment with a stomatologist is organized to make and adjust a thermo-molded type MAD.

An initial assessment is carried out for all patients during a day hospitalization specific to the study (study of endothelial function, blood pressure, Osler test, ECG, venous and urinary sampling, and completion of the study questionnaires).

Patients are then asked to stop CPAP treatment for two weeks. Patients in the OAM group use OAM during this period. Patients in the control group do not receive any specific treatment for their OSAHS during this period.

After 2 weeks of stopping CPAP, a second assessment, identical to the initial assessment, is carried out for all patients. This assessment is carried out during one night of hospitalization which also allows a PSG to be carried out under OAM or without treatment.

At the end of this assessment, the study is terminated and the patients resume their usual use of CPAP.

03

Conditions studied

  • Sleep Apnea, Obstructive
  • Endothelial Dysfunction
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient accepting MAD treatment
  • Patient with an apnea-hypopnea index (AHI) greater than 15 events per hour on the initial recording
  • Patient with excessive daytime sleepiness during initial treatment (ESE>10)
  • Patient treated for more than 12 months by CPAP with average compliance greater than 5 hours per night

Exclusion criteria

Exclusion Criteria:

  • Initial severe daytime sleepiness characterized
  • OSAS with ≥ 5 central apneas per hour of sleep at baseline recording
  • Previously diagnosed severe cardiac and/or respiratory pathology:
  • ≥ 35 kg/m2
  • Known to OAM treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    control group

    Patients will be ask not to use any OSAS treatment during the 2 weeks of the study (after the CPAP withdrawal)

  • Experimental
    mandibular advancement device

    Patients will be asked to use mandibular advancement device during the 2 weeks CPAP withdrawal

    Device: Mandibular advancement device treatment

Interventions

  • DeviceMandibular advancement device treatment

    a titratable thermoplastic mandibular advancement device will be proposed to patient in the experimental group during the 2 weeks of CPAP withdrawal.

06

What researchers measure

Primary outcomes

  1. Change in subjective sleepiness

    Sleepiness assessed using the Epworth Sleepiness Scale

    Time frame: before and two weeks after CPAP withdrawal

Secondary outcomes

  1. Change in objective sleepiness

    Osler test

    Time frame: before and two weeks after CPAP withdrawal

  2. Change in subjective sleep quality

    Pittsburgh sleep quality index

    Time frame: before and two weeks after CPAP withdrawal

  3. Change in executive function

    trail making test

    Time frame: before and two weeks after CPAP withdrawal

  4. Change in 24 hour blood pressure

    24 hours systolic, diastolic and mean blood pressure (Blood pressure holter)

    Time frame: before and two weeks after CPAP withdrawal

  5. Change in endothelial function

    endothelial function (assessed by reactive hyperemia arterial tonometry)

    Time frame: before and two weeks after CPAP withdrawal

  6. Change in cardiac repolarization

    cardiac repolarization (QTc, TpTec intervals calculation on electrocardiographe))

    Time frame: before and two weeks after CPAP withdrawal

  7. Change in catecholamines levels

    urine catecholamines levels

    Time frame: before and two weeks after CPAP withdrawal

  8. Change in glucose levels

    blood glucose levels

    Time frame: before and two weeks after CPAP withdrawal

  9. Change in Microparticles

    blood microparticles levels

    Time frame: before and two weeks after CPAP withdrawal

  10. Change in oxydative stress

    blood 8-isoprostane levels

    Time frame: before and two weeks after CPAP withdrawal

  11. Change in inflammation

    blood CRPus levels

    Time frame: before and two weeks after CPAP withdrawal

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Nov 2026, 32 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 32 months is close to that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2023
First posted
Jul 11, 2023
StartActual
Mar 5, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05939934
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Mar 5, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

wojciech trzepizur, MD PHD
Contact
wotrezpizur@chu-angers.fr
+3380575272
wojciech Trzepizur, MD PHD
principal investigator · University Hospital, Angers

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion